Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
Fly Intel: Top five analyst downgrades » 09:54
04/12/21
04/12
09:54
04/12/21
09:54
QCOM

Qualcomm

$139.10 /

-1.52 (-1.08%)

, JKS

JinkoSolar

$36.80 /

-1.86 (-4.81%)

, GME

GameStop

$159.43 /

+1.39 (+0.88%)

, AZN

AstraZeneca

$49.58 /

-0.37 (-0.74%)

, KNX

Knight-Swift

$49.85 /

-0.24 (-0.48%)

Catch up on today's…

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) downgraded to In Line from Outperform at Evercore ISI with analyst C.J. Muse saying he now believes "the lion's share" of the 5G smartphone upcycle is priced into the stock price and looking ahead Muse sees sentiment on Qualcomm related to Apple turning from 5G design win to potential insourcing. 2. JinkoSolar (JKS) downgraded to Neutral from Buy at Roth Capital with analyst Philip Shen saying JinkoSolar delivered a Q4 miss and weak Q1 guidance that he looks for the stock to be weak until the outlook for volume and margins improves, adding that it is unclear when that will happen. 3. GameStop (GME) downgraded to Sell from Hold at Ascendiant with analyst Edward Woo saying the Reddit trading surge "is likely to fade as "digital threats increases." 4. AstraZeneca (AZN) downgraded to Hold from Buy at Argus with analyst David Toung saying the rating change reflects his concerns that the company's COVID-19 vaccine AZD1222 may not receive emergency use authorization from the FDA due to safety issues emerging in Europe. 5. Knight-Swift (KNX) downgraded to Neutral from Positive at Susquehanna with analyst Bascome Majors citing valuation for his downgrade as he believes 2021 is likely the peak of this truckload cycle and his work suggests that all trucking-related stocks eventually de-rate cyclically. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
QCOM Qualcomm
$139.10 /

-1.52 (-1.08%)

KNX Knight-Swift
$49.85 /

-0.24 (-0.48%)

JKS JinkoSolar
$36.80 /

-1.86 (-4.81%)

GME GameStop
$159.43 /

+1.39 (+0.88%)

AZN AstraZeneca
$49.58 /

-0.37 (-0.74%)

QCOM Qualcomm
$139.10 /

-1.52 (-1.08%)

04/12/21 Evercore ISI
Evercore downgrades Qualcomm to In Line, sees most of 5G upside priced in
04/12/21 Evercore ISI
Qualcomm downgraded to In Line from Outperform at Evercore ISI
03/24/21 Evercore ISI
Intel price target raised to $75 from $68 at Evercore ISI
03/17/21 JPMorgan
Apple chip transition an overhang on Qualcomm shares, says JPMorgan
JKS JinkoSolar
$36.80 /

-1.86 (-4.81%)

04/12/21 Roth Capital
JinkoSolar downgraded to Neutral from Buy at Roth Capital
04/12/21 Roth Capital
JinkoSolar downgraded to Neutral from Buy at Roth Capital
02/08/21 Roth Capital
Bill could be 'meaningful positive' for solar stocks, says Roth Capital
01/04/21 Goldman Sachs
JinkoSolar price target raised to $39 from $34 at Goldman Sachs
GME GameStop
$159.43 /

+1.39 (+0.88%)

04/12/21 Ascendiant
GameStop downgraded to Sell from Hold at Ascendiant
04/06/21 BofA
BofA keeps $10 target on GameStop despite 'positive' funding news
04/05/21 Telsey Advisory
Telsey keeps Underperform rating on GameStop after Q1 update, ATM program bump
03/24/21
Fly Intel: Top five analyst downgrades
AZN AstraZeneca
$49.58 /

-0.37 (-0.74%)

04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/12/21 Argus
AstraZeneca downgraded to Hold from Buy at Argus
04/12/21 Argus
AstraZeneca downgraded to Hold from Buy at Argus
04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
KNX Knight-Swift
$49.85 /

-0.24 (-0.48%)

04/12/21 Susquehanna
Knight-Swift downgraded to Neutral at Susquehanna
04/12/21 Susquehanna
Knight-Swift downgraded to Neutral from Positive at Susquehanna
03/26/21 Vertical Research
Knight-Swift reinstated with a Buy at Vertical Research
03/11/21 UBS
Knight-Swift downgraded to Neutral from Buy at UBS
QCOM Qualcomm
$139.10 /

-1.52 (-1.08%)

KNX Knight-Swift
$49.85 /

-0.24 (-0.48%)

JKS JinkoSolar
$36.80 /

-1.86 (-4.81%)

GME GameStop
$159.43 /

+1.39 (+0.88%)

AZN AstraZeneca
$49.58 /

-0.37 (-0.74%)

QCOM Qualcomm
$139.10 /

-1.52 (-1.08%)

JKS JinkoSolar
$36.80 /

-1.86 (-4.81%)

GME GameStop
$159.43 /

+1.39 (+0.88%)

AZN AstraZeneca
$49.58 /

-0.37 (-0.74%)

QCOM Qualcomm
$139.10 /

-1.52 (-1.08%)

JKS JinkoSolar
$36.80 /

-1.86 (-4.81%)

GME GameStop
$159.43 /

+1.39 (+0.88%)

AZN AstraZeneca
$49.58 /

-0.37 (-0.74%)

QCOM Qualcomm
$139.10 /

-1.52 (-1.08%)

JKS JinkoSolar
$36.80 /

-1.86 (-4.81%)

GME GameStop
$159.43 /

+1.39 (+0.88%)

AZN AstraZeneca
$49.58 /

-0.37 (-0.74%)

Recommendations
B. Riley calls Agenus the next Seagen, reiterates $8 target » 08:33
04/12/21
04/12
08:33
04/12/21
08:33
AGEN

Agenus

$2.78 /

-0.01 (-0.36%)

, MRK

Merck

$76.33 /

+0.855 (+1.13%)

, BMY

Bristol-Myers

$62.61 /

+0.695 (+1.12%)

, AZN

AstraZeneca

$49.95 /

+0.465 (+0.94%)

, RHHBY

Roche

$41.93 /

+0.53 (+1.28%)

, SGEN

Seagen

$142.81 /

-1.68 (-1.16%)

B. Riley analyst Mayank…

B. Riley analyst Mayank Mamtani reiterates a Buy rating on Agenus (AGEN) with an $8 price target coming away from American Association for Cancer Research annual meeting. The analyst gained "incremental visibility" into the potential of Agenus' immune-oncology platform, which he says is "leapfrogging industry bellwethers" like Merck (MRK), Bristol-Myers (BMY), AstraZeneca (AZ) and Roche (Roche). Mamtani believes Agenus is the next Seagen (SGEN). The analyst highlights the "breakthrough potential" of Agenus' pipeline as incremental clinical data matures from AGEN1181. This is similar to what was observed with Seagen originally when it was primarily an Adcetris-centric story with substantial value ascribed in recent years with strong execution across multiple high-value programs towards registration, Mamtani tells investors in a research note.

ShowHide Related Items >><<
SGEN Seagen
$142.81 /

-1.68 (-1.16%)

RHHBY Roche
$41.93 /

+0.53 (+1.28%)

MRK Merck
$76.33 /

+0.855 (+1.13%)

BMY Bristol-Myers
$62.61 /

+0.695 (+1.12%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AGEN Agenus
$2.78 /

-0.01 (-0.36%)

AGEN Agenus
$2.78 /

-0.01 (-0.36%)

09/22/20 B. Riley
B. Riley FBR calls Agenus 'hidden gem' amidst ESMO data releases
09/18/20 Jefferies
Agenus price target raised to $8 from $5 at Jefferies
MRK Merck
$76.33 /

+0.855 (+1.13%)

04/08/21 Alliance Global Partners
Alliance Global Partners sees Fast Track for Immutep efti as meaningful positive
04/08/21 H.C. Wainwright
Alkermes collaboration not as big as investors wanted, says H.C. Wainwright
04/07/21 Mizuho
Mizuho sees Alkermes, Merck collaboration as important next step for nemvaleukin
04/06/21 RBC Capital
Merck transferred with a Sector Perform at RBC Capital
BMY Bristol-Myers
$62.61 /

+0.695 (+1.12%)

03/08/21 BofA
Gartner added to US 1 List, Bristol-Myers removed at BofA
02/12/21 Morgan Stanley
Amgen court decision may have readthrough for Gilead, says Morgan Stanley
02/02/21 BTIG
Prothena upgraded to Buy at BTIG on birtamimab 'revival'
01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

04/12/21 Argus
AstraZeneca downgraded to Hold from Buy at Argus
04/12/21 Argus
AstraZeneca downgraded to Hold from Buy at Argus
04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
RHHBY Roche
$41.93 /

+0.53 (+1.28%)

03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
03/23/21 BMO Capital
Ionis Pharmaceuticals price target lowered to $76 from $90 at BMO Capital
SGEN Seagen
$142.81 /

-1.68 (-1.16%)

03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
02/16/21 RBC Capital
Seagen price target lowered to $169 from $186 at RBC Capital
02/12/21 Barclays
Seagen price target lowered to $168 from $177 at Barclays
SGEN Seagen
$142.81 /

-1.68 (-1.16%)

RHHBY Roche
$41.93 /

+0.53 (+1.28%)

MRK Merck
$76.33 /

+0.855 (+1.13%)

BMY Bristol-Myers
$62.61 /

+0.695 (+1.12%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AGEN Agenus
$2.78 /

-0.01 (-0.36%)

RHHBY Roche
$41.93 /

+0.53 (+1.28%)

MRK Merck
$76.33 /

+0.855 (+1.13%)

BMY Bristol-Myers
$62.61 /

+0.695 (+1.12%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

SGEN Seagen
$142.81 /

-1.68 (-1.16%)

RHHBY Roche
$41.93 /

+0.53 (+1.28%)

MRK Merck
$76.33 /

+0.855 (+1.13%)

BMY Bristol-Myers
$62.61 /

+0.695 (+1.12%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

MRK Merck
$76.33 /

+0.855 (+1.13%)

BMY Bristol-Myers
$62.61 /

+0.695 (+1.12%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

Downgrade
AstraZeneca downgraded to Hold from Buy at Argus » 07:18
04/12/21
04/12
07:18
04/12/21
07:18
AZN

AstraZeneca

$49.95 /

+0.465 (+0.94%)

Argus analyst David Toung…

Argus analyst David Toung downgraded AstraZeneca to Hold from Buy. The rating change reflects his concerns that the company's COVID-19 vaccine AZD1222 may not receive emergency use authorization from the FDA due to safety issues emerging in Europe, the analyst tells investors in a research note, stating that the blood clot issue has led governments in the U.K. and many European countries to restrict the use of AZD1222. Toung further notes that manufacturing errors that led to AstraZeneca discarding millions of doses compound the impact on public confidence in AZD1222 and, in turn, on potential revenue and earnings from the vaccine.

ShowHide Related Items >><<
AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

04/12/21 Argus
AstraZeneca downgraded to Hold from Buy at Argus
04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
03/23/21 Societe Generale
AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale
AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

Hot Stocks
Zentalis enters collaboration, supply agreement with GSK for ZN-c3 » 07:11
04/12/21
04/12
07:11
04/12/21
07:11
ZNTL

Zentalis

$37.35 /

-5.19 (-12.20%)

, GSK

GlaxoSmithKline

$36.64 /

+0.175 (+0.48%)

Zentalis Pharmaceuticals…

Zentalis Pharmaceuticals (ZNTL) announced a clinical collaboration agreement with GlaxoSmithKline (GSK) in which Zentalis will evaluate the combination of ZN-c3, Zentalis' oral WEE1 inhibitor product candidate, and ZEJULA, GSK's poly polymerase inhibitor, in patients with advanced epithelial ovarian cancer. Zentalis is currently conducting clinical studies with ZN-c3 both as a monotherapy and in combination with certain standard of care therapies. Under the terms of the non-exclusive collaboration, Zentalis is responsible for conducting the study with GSK providing all required doses of niraparib. Zentalis maintains full ownership of ZN-c3.

ShowHide Related Items >><<
ZNTL Zentalis
$37.35 /

-5.19 (-12.20%)

GSK GlaxoSmithKline
$36.64 /

+0.175 (+0.48%)

ZNTL Zentalis
$37.35 /

-5.19 (-12.20%)

03/26/21 H.C. Wainwright
Zentalis price target raised to $65 from $43 at H.C. Wainwright
01/19/21 Wedbush
Zentalis initiated with an Outperform at Wedbush
09/28/20 Cantor Fitzgerald
Cantor starts 'underappreciated' Zentalis with Overweight, $44 target
09/28/20 Cantor Fitzgerald
Zentalis initiated with an Overweight at Cantor Fitzgerald
GSK GlaxoSmithKline
$36.64 /

+0.175 (+0.48%)

03/23/21
Fly Intel: Top five analyst downgrades
03/23/21 SVB Leerink
SVB Leerink moving to sidelines on Alexion, five others on industry concerns
03/23/21 SVB Leerink
GlaxoSmithKline downgraded to Market Perform from Outperform at SVB Leerink
03/08/21 JPMorgan
JPMorgan double downgrades AnaptysBio back to Underweight after trial miss
ZNTL Zentalis
$37.35 /

-5.19 (-12.20%)

GSK GlaxoSmithKline
$36.64 /

+0.175 (+0.48%)

  • 30
    Jul
GSK GlaxoSmithKline
$36.64 /

+0.175 (+0.48%)

GSK GlaxoSmithKline
$36.64 /

+0.175 (+0.48%)

ZNTL Zentalis
$37.35 /

-5.19 (-12.20%)

Downgrade
AstraZeneca downgraded to Hold from Buy at Argus » 07:09
04/12/21
04/12
07:09
04/12/21
07:09
AZN

AstraZeneca

$49.95 /

+0.465 (+0.94%)

Argus analyst David Toung…

Argus analyst David Toung downgraded AstraZeneca to Hold from Buy.

ShowHide Related Items >><<
AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
03/23/21 Societe Generale
AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale
03/18/21 Deutsche Bank
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank
AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

Hot Stocks
AstraZeneca's DARE-19 ph.3 trial of Farxiga in COVID-19 failed primary endpoint » 06:09
04/12/21
04/12
06:09
04/12/21
06:09
AZN

AstraZeneca

$49.95 /

+0.465 (+0.94%)

The company states:…

The company states: "AstraZeneca and Saint Luke's Mid America Heart Institute today announced high-level results of the primary analysis from the DARE-19 Phase III trial assessing the potential of Farxiga to treat patients hospitalised with COVID-19 who are at risk of developing serious complications. The trial did not achieve statistical significance for the primary endpoint of prevention measuring organ dysfunction and all-cause mortality, and the primary endpoint of recovery measuring a change in clinical status, at 30 days. DARE-19 was the first Phase III trial to evaluate the safety and efficacy of a sodium-glucose co-transporter-2 inhibitor in patients hospitalised with COVID-19 who also have risk factors for developing serious complications, including hypertension, type-2 diabetes, atherosclerotic cardiovascular disease, heart failure or chronic kidney disease Stages 3-4. Cardiac, renal and metabolic comorbidities have been associated with poor outcomes and death in patients hospitalised with COVID-19." Reference Link

ShowHide Related Items >><<
AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
03/23/21 Societe Generale
AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale
03/18/21 Deutsche Bank
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank
AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

Friday
On The Fly
Fly Intel: Wall Street's top stories for Friday » 16:39
04/09/21
04/09
16:39
04/09/21
16:39
BA

Boeing

$252.36 /

-2.5 (-0.98%)

, AMZN

Amazon.com

$3,371.40 /

+73.69 (+2.23%)

, CCK

Crown Holdings

$104.85 /

+2.86 (+2.80%)

, AZN

AstraZeneca

$49.95 /

+0.465 (+0.94%)

, JNJ

Johnson & Johnson

$161.20 /

-1.74 (-1.07%)

, PFE

Pfizer

$36.60 /

+0.64 (+1.78%)

, BNTX

BioNTech

$122.15 /

+7.68 (+6.71%)

, FUBO

FuboTV

$23.30 /

+2.605 (+12.59%)

, LEVI

Levi Strauss

$25.69 /

+0.675 (+2.70%)

, PRVB

Provention Bio

$8.00 /

-1.72 (-17.70%)

, JKS

JinkoSolar

$38.66 /

-0.2 (-0.51%)

The major averages closed…

ShowHide Related Items >><<
PRVB Provention Bio
$8.00 /

-1.72 (-17.70%)

PFE Pfizer
$36.60 /

+0.64 (+1.78%)

LEVI Levi Strauss
$25.69 /

+0.675 (+2.70%)

JNJ Johnson & Johnson
$161.20 /

-1.74 (-1.07%)

JKS JinkoSolar
$38.66 /

-0.2 (-0.51%)

FUBO FuboTV
$23.30 /

+2.605 (+12.59%)

CCK Crown Holdings
$104.85 /

+2.86 (+2.80%)

BNTX BioNTech
$122.15 /

+7.68 (+6.71%)

BA Boeing
$252.36 /

-2.5 (-0.98%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AMZN Amazon.com
$3,371.40 /

+73.69 (+2.23%)

BA Boeing
$252.36 /

-2.5 (-0.98%)

04/09/21 Baird
Baird says add to Boeing on any weakness due to 'tiny fix' needed for MAX jets
03/29/21 Goldman Sachs
Boeing resuming 787 deliveries removes overhang, says Goldman Sachs
03/19/21 Susquehanna
Boeing price target raised to $300 from $250 at Susquehanna
03/15/21 Morgan Stanley
Aerospace sector upgraded to Attractive from Cautious at Morgan Stanley
AMZN Amazon.com
$3,371.40 /

+73.69 (+2.23%)

04/05/21 Evercore ISI
Amazon.com assumed with an Outperform at Evercore ISI
04/01/21 Wedbush
Microsoft gets another major win within the beltway, says Wedbush
04/01/21 Credit Suisse
Ubiquiti price target lowered to $126 from $157 at Credit Suisse
03/31/21 Wolfe Research
Amazon.com assumed with an Outperform at Wolfe Research
CCK Crown Holdings
$104.85 /

+2.86 (+2.80%)

04/09/21 Goldman Sachs
Crown Holdings initiated with a Neutral at Goldman Sachs
02/11/21 Citi
Crown Holdings price target raised to $125 from $117 at Citi
02/11/21 Barclays
Crown Holdings price target raised to $122 from $103 at Barclays
01/26/21 BMO Capital
Sonoco Products downgraded to Market Perform from Outperform at BMO Capital
AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
03/23/21 Societe Generale
AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale
03/18/21 Deutsche Bank
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank
JNJ Johnson & Johnson
$161.20 /

-1.74 (-1.07%)

04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
PFE Pfizer
$36.60 /

+0.64 (+1.78%)

04/09/21
Pfizer to host conference call
04/06/21 RBC Capital
Pfizer transferred with a Sector Perform at RBC Capital
03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
BNTX BioNTech
$122.15 /

+7.68 (+6.71%)

01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
FUBO FuboTV
$23.30 /

+2.605 (+12.59%)

04/05/21 Evercore ISI
FuboTV assumed with an Outperform at Evercore ISI
03/29/21 Needham
Needham lays out 'bull case' on 'inexpensive' FuboTV shares
03/09/21 Oppenheimer
FuboTV price target lowered to $35 from $45 at Oppenheimer
03/08/21 Alliance Global Partners
Chicken Soup for the Soul initiated with a Buy at Alliance Global Partners
LEVI Levi Strauss
$25.69 /

+0.675 (+2.70%)

04/09/21 UBS
Levi Strauss price target raised to $34 from $29 at UBS
04/09/21 Citi
Levi Strauss price target raised to $29 from $25 at Citi
01/27/21 Citi
Levi Strauss price target raised to $25 from $19 at Citi
01/07/21 JPMorgan
Levi Strauss price target raised to $21 from $18 at JPMorgan
PRVB Provention Bio
$8.00 /

-1.72 (-17.70%)

04/09/21 SVB Leerink
Provention Bio price target lowered to $16 from $26 at SVB Leerink
04/09/21 RBC Capital
Provention Bio cut to Sector Perform at RBC Capital after teplizumab FDA notice
04/09/21 Cantor Fitzgerald
Provention Bio price target lowered to $25 from $27 at Cantor Fitzgerald
04/09/21 RBC Capital
Provention Bio downgraded to Sector Perform from Outperform at RBC Capital
JKS JinkoSolar
$38.66 /

-0.2 (-0.51%)

02/08/21 Roth Capital
Bill could be 'meaningful positive' for solar stocks, says Roth Capital
01/04/21 Goldman Sachs
JinkoSolar price target raised to $39 from $34 at Goldman Sachs
12/30/20 GLJ Research
GLJ Research keeps Sell on JinkoSolar after chairman, CEO dump shares
12/21/20 Roth Capital
ITC/PTC extensions likely included in COVID relief package, says Roth Capital
PRVB Provention Bio
$8.00 /

-1.72 (-17.70%)

PFE Pfizer
$36.60 /

+0.64 (+1.78%)

LEVI Levi Strauss
$25.69 /

+0.675 (+2.70%)

JNJ Johnson & Johnson
$161.20 /

-1.74 (-1.07%)

JKS JinkoSolar
$38.66 /

-0.2 (-0.51%)

FUBO FuboTV
$23.30 /

+2.605 (+12.59%)

CCK Crown Holdings
$104.85 /

+2.86 (+2.80%)

BA Boeing
$252.36 /

-2.5 (-0.98%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AMZN Amazon.com
$3,371.40 /

+73.69 (+2.23%)

  • 14
    Jan
  • 30
    Dec
  • 08
    Oct
  • 23
    Jul
  • 18
    Jun
PFE Pfizer
$36.60 /

+0.64 (+1.78%)

JNJ Johnson & Johnson
$161.20 /

-1.74 (-1.07%)

JKS JinkoSolar
$38.66 /

-0.2 (-0.51%)

CCK Crown Holdings
$104.85 /

+2.86 (+2.80%)

BA Boeing
$252.36 /

-2.5 (-0.98%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AMZN Amazon.com
$3,371.40 /

+73.69 (+2.23%)

PRVB Provention Bio
$8.00 /

-1.72 (-17.70%)

PFE Pfizer
$36.60 /

+0.64 (+1.78%)

LEVI Levi Strauss
$25.69 /

+0.675 (+2.70%)

JNJ Johnson & Johnson
$161.20 /

-1.74 (-1.07%)

JKS JinkoSolar
$38.66 /

-0.2 (-0.51%)

FUBO FuboTV
$23.30 /

+2.605 (+12.59%)

CCK Crown Holdings
$104.85 /

+2.86 (+2.80%)

BA Boeing
$252.36 /

-2.5 (-0.98%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AMZN Amazon.com
$3,371.40 /

+73.69 (+2.23%)

PFE Pfizer
$36.60 /

+0.64 (+1.78%)

LEVI Levi Strauss
$25.69 /

+0.675 (+2.70%)

JNJ Johnson & Johnson
$161.20 /

-1.74 (-1.07%)

JKS JinkoSolar
$38.66 /

-0.2 (-0.51%)

FUBO FuboTV
$23.30 /

+2.605 (+12.59%)

BNTX BioNTech
$122.15 /

+7.68 (+6.71%)

BA Boeing
$252.36 /

-2.5 (-0.98%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AMZN Amazon.com
$3,371.40 /

+73.69 (+2.23%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:54
04/09/21
04/09
12:54
04/09/21
12:54
BA

Boeing

$251.71 /

-3.15 (-1.24%)

, AMZN

Amazon.com

$3,352.25 /

+54.54 (+1.65%)

, CCK

Crown Holdings

$104.06 /

+2.07 (+2.03%)

, AZN

AstraZeneca

$49.80 /

+0.315 (+0.64%)

, JNJ

Johnson & Johnson

$159.95 /

-2.99 (-1.84%)

, AFMD

Affimed

$9.73 /

+1.86 (+23.63%)

, LEVI

Levi Strauss

$25.48 /

+0.465 (+1.86%)

, PRVB

Provention Bio

$8.20 /

-1.52 (-15.64%)

, JKS

JinkoSolar

$38.04 /

-0.82 (-2.11%)

The major averages are…

ShowHide Related Items >><<
PRVB Provention Bio
$8.20 /

-1.52 (-15.64%)

LEVI Levi Strauss
$25.48 /

+0.465 (+1.86%)

JNJ Johnson & Johnson
$159.95 /

-2.99 (-1.84%)

JKS JinkoSolar
$38.04 /

-0.82 (-2.11%)

CCK Crown Holdings
$104.06 /

+2.07 (+2.03%)

BA Boeing
$251.71 /

-3.15 (-1.24%)

AZN AstraZeneca
$49.80 /

+0.315 (+0.64%)

AMZN Amazon.com
$3,352.25 /

+54.54 (+1.65%)

AFMD Affimed
$9.73 /

+1.86 (+23.63%)

BA Boeing
$251.71 /

-3.15 (-1.24%)

04/09/21 Baird
Baird says add to Boeing on any weakness due to 'tiny fix' needed for MAX jets
03/29/21 Goldman Sachs
Boeing resuming 787 deliveries removes overhang, says Goldman Sachs
03/19/21 Susquehanna
Boeing price target raised to $300 from $250 at Susquehanna
03/15/21 Morgan Stanley
Aerospace sector upgraded to Attractive from Cautious at Morgan Stanley
AMZN Amazon.com
$3,352.25 /

+54.54 (+1.65%)

04/05/21 Evercore ISI
Amazon.com assumed with an Outperform at Evercore ISI
04/01/21 Wedbush
Microsoft gets another major win within the beltway, says Wedbush
04/01/21 Credit Suisse
Ubiquiti price target lowered to $126 from $157 at Credit Suisse
03/31/21 Wolfe Research
Amazon.com assumed with an Outperform at Wolfe Research
CCK Crown Holdings
$104.06 /

+2.07 (+2.03%)

04/09/21 Goldman Sachs
Crown Holdings initiated with a Neutral at Goldman Sachs
02/11/21 Citi
Crown Holdings price target raised to $125 from $117 at Citi
02/11/21 Barclays
Crown Holdings price target raised to $122 from $103 at Barclays
01/26/21 BMO Capital
Sonoco Products downgraded to Market Perform from Outperform at BMO Capital
AZN AstraZeneca
$49.80 /

+0.315 (+0.64%)

04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
03/23/21 Societe Generale
AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale
03/18/21 Deutsche Bank
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank
JNJ Johnson & Johnson
$159.95 /

-2.99 (-1.84%)

04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
AFMD Affimed
$9.73 /

+1.86 (+23.63%)

03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/24/21 Wells Fargo
Affimed N.V. price target raised to $15 from $10 at Wells Fargo
03/10/21 BMO Capital
BMO Capital ups Affimed N.V. target to $12 following AFM13 interim analysis
LEVI Levi Strauss
$25.48 /

+0.465 (+1.86%)

04/09/21 UBS
Levi Strauss price target raised to $34 from $29 at UBS
04/09/21 Citi
Levi Strauss price target raised to $29 from $25 at Citi
01/27/21 Citi
Levi Strauss price target raised to $25 from $19 at Citi
01/07/21 JPMorgan
Levi Strauss price target raised to $21 from $18 at JPMorgan
PRVB Provention Bio
$8.20 /

-1.52 (-15.64%)

04/09/21 SVB Leerink
Provention Bio price target lowered to $16 from $26 at SVB Leerink
04/09/21 RBC Capital
Provention Bio cut to Sector Perform at RBC Capital after teplizumab FDA notice
04/09/21 Cantor Fitzgerald
Provention Bio price target lowered to $25 from $27 at Cantor Fitzgerald
04/09/21 RBC Capital
Provention Bio downgraded to Sector Perform from Outperform at RBC Capital
JKS JinkoSolar
$38.04 /

-0.82 (-2.11%)

02/08/21 Roth Capital
Bill could be 'meaningful positive' for solar stocks, says Roth Capital
01/04/21 Goldman Sachs
JinkoSolar price target raised to $39 from $34 at Goldman Sachs
12/30/20 GLJ Research
GLJ Research keeps Sell on JinkoSolar after chairman, CEO dump shares
12/21/20 Roth Capital
ITC/PTC extensions likely included in COVID relief package, says Roth Capital
PRVB Provention Bio
$8.20 /

-1.52 (-15.64%)

LEVI Levi Strauss
$25.48 /

+0.465 (+1.86%)

JNJ Johnson & Johnson
$159.95 /

-2.99 (-1.84%)

JKS JinkoSolar
$38.04 /

-0.82 (-2.11%)

CCK Crown Holdings
$104.06 /

+2.07 (+2.03%)

BA Boeing
$251.71 /

-3.15 (-1.24%)

AZN AstraZeneca
$49.80 /

+0.315 (+0.64%)

AMZN Amazon.com
$3,352.25 /

+54.54 (+1.65%)

  • 14
    Jan
  • 13
    Jan
  • 18
    Jun
JNJ Johnson & Johnson
$159.95 /

-2.99 (-1.84%)

JKS JinkoSolar
$38.04 /

-0.82 (-2.11%)

CCK Crown Holdings
$104.06 /

+2.07 (+2.03%)

BA Boeing
$251.71 /

-3.15 (-1.24%)

AZN AstraZeneca
$49.80 /

+0.315 (+0.64%)

AMZN Amazon.com
$3,352.25 /

+54.54 (+1.65%)

PRVB Provention Bio
$8.20 /

-1.52 (-15.64%)

LEVI Levi Strauss
$25.48 /

+0.465 (+1.86%)

JNJ Johnson & Johnson
$159.95 /

-2.99 (-1.84%)

JKS JinkoSolar
$38.04 /

-0.82 (-2.11%)

CCK Crown Holdings
$104.06 /

+2.07 (+2.03%)

BA Boeing
$251.71 /

-3.15 (-1.24%)

AZN AstraZeneca
$49.80 /

+0.315 (+0.64%)

AMZN Amazon.com
$3,352.25 /

+54.54 (+1.65%)

AFMD Affimed
$9.73 /

+1.86 (+23.63%)

LEVI Levi Strauss
$25.48 /

+0.465 (+1.86%)

JNJ Johnson & Johnson
$159.95 /

-2.99 (-1.84%)

JKS JinkoSolar
$38.04 /

-0.82 (-2.11%)

BA Boeing
$251.71 /

-3.15 (-1.24%)

AZN AstraZeneca
$49.80 /

+0.315 (+0.64%)

AMZN Amazon.com
$3,352.25 /

+54.54 (+1.65%)

Periodicals
AstraZeneca slashes vaccine deliveries to EU by 49%, FT reports » 11:29
04/09/21
04/09
11:29
04/09/21
11:29
AZN

AstraZeneca

$49.85 /

+0.365 (+0.74%)

AstraZeneca has reduced…

AstraZeneca has reduced the number of COVID-19 vaccine doses it will deliver to EU nations this week by nearly half, the Finiancial Times' Donato Paolo Mancini, Hannah Kuchler, and Michael Peel reports. The company now anticipates delivering roughly 1.3M shots to the EU's 27 nations, plus Iceland and Norway, down from the 2.6M target it established last month, the authors say, citing documents seen by the FT. The reduction is equivalent to a 49% slashing and is evenly distributed across member states, the authors note. Reference Link

ShowHide Related Items >><<
AZN AstraZeneca
$49.85 /

+0.365 (+0.74%)

AZN AstraZeneca
$49.85 /

+0.365 (+0.74%)

04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
03/23/21 Societe Generale
AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale
03/18/21 Deutsche Bank
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank
AZN AstraZeneca
$49.85 /

+0.365 (+0.74%)

AZN AstraZeneca
$49.85 /

+0.365 (+0.74%)

AZN AstraZeneca
$49.85 /

+0.365 (+0.74%)

AZN AstraZeneca
$49.85 /

+0.365 (+0.74%)

Periodicals
EU evaluates J&J vaccine for blood clots, widens AstraZeneca probe, Reuters says » 10:07
04/09/21
04/09
10:07
04/09/21
10:07
AZN

AstraZeneca

$49.96 /

+0.475 (+0.96%)

, JNJ

Johnson & Johnson

$161.97 /

-0.97 (-0.60%)

The European Medicines…

The European Medicines Agency is evaluating reports of a bleeding condition in people after receiving AstraZeneca's (AZN) COVID-19 vaccine as well as reviewing Johnson & Johnson's (JNJ) shot over reports of rare blood clots, Reuters' reports, citing the agency. The EMA said four serious cases of rare blood clots with low platelets, one of which was fatal, have been reported after inoculation with J&J's vaccine and five cases of capillary leak syndrome linked to AstraZeneca's vaccine were reported. Reference Link

ShowHide Related Items >><<
JNJ Johnson & Johnson
$161.97 /

-0.97 (-0.60%)

AZN AstraZeneca
$49.96 /

+0.475 (+0.96%)

AZN AstraZeneca
$49.96 /

+0.475 (+0.96%)

04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
03/23/21 Societe Generale
AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale
03/18/21 Deutsche Bank
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank
JNJ Johnson & Johnson
$161.97 /

-0.97 (-0.60%)

04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
JNJ Johnson & Johnson
$161.97 /

-0.97 (-0.60%)

AZN AstraZeneca
$49.96 /

+0.475 (+0.96%)

JNJ Johnson & Johnson
$161.97 /

-0.97 (-0.60%)

AZN AstraZeneca
$49.96 /

+0.475 (+0.96%)

JNJ Johnson & Johnson
$161.97 /

-0.97 (-0.60%)

AZN AstraZeneca
$49.96 /

+0.475 (+0.96%)

JNJ Johnson & Johnson
$161.97 /

-0.97 (-0.60%)

AZN AstraZeneca
$49.96 /

+0.475 (+0.96%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.